273 related articles for article (PubMed ID: 18035517)
21. [Renal cell carcinoma management and therapies in 2010].
Albouy B; Gross Goupil M; Escudier B; Massard C
Bull Cancer; 2010; 97():17-28. PubMed ID: 20418201
[TBL] [Abstract][Full Text] [Related]
22. Systemic therapy for metastatic renal cell carcinoma.
Kroog GS; Motzer RJ
Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
[TBL] [Abstract][Full Text] [Related]
23. Targeted therapies for kidney cancer in urologic practice.
Haas NB; Uzzo RG
Urol Oncol; 2007; 25(5):420-32. PubMed ID: 17826664
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor-targeted therapy in metastatic renal cell carcinoma.
Rini BI
Cancer; 2009 May; 115(10 Suppl):2306-12. PubMed ID: 19402073
[TBL] [Abstract][Full Text] [Related]
25. New treatment approaches in metastatic renal cell carcinoma.
Mancuso A; Sternberg CN
Curr Opin Urol; 2006 Sep; 16(5):337-41. PubMed ID: 16905978
[TBL] [Abstract][Full Text] [Related]
26. Treatment options in renal cell carcinoma: past, present and future.
Oudard S; George D; Medioni J; Motzer R
Ann Oncol; 2007 Sep; 18 Suppl 10():x25-31. PubMed ID: 17761720
[TBL] [Abstract][Full Text] [Related]
27. Major treatment improvements encourage kidney cancer researchers to seek further gains.
Tuma RS
J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
[No Abstract] [Full Text] [Related]
28. Treatment options for metastatic renal cell carcinoma: a review.
Athar U; Gentile TC
Can J Urol; 2008 Apr; 15(2):3954-66. PubMed ID: 18405442
[TBL] [Abstract][Full Text] [Related]
29. [Interdisciplinary recommendations for the treatment of metastatic renal cell carcinoma].
Miller K; Bergmann L; Jäger E; Jakse G; Wirth M; Keilholz U;
Aktuelle Urol; 2009 Jan; 40(1):27-30. PubMed ID: 19177318
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapies for the treatment of metastatic renal cell carcinoma: clinical evidence.
Hutson TE
Oncologist; 2011; 16 Suppl 2(Suppl 2):14-22. PubMed ID: 21346036
[TBL] [Abstract][Full Text] [Related]
31. Targeted therapies in metastatic renal cancer in 2009.
Bastien L; Culine S; Paule B; Ledbai S; Patard JJ; de la Taille A
BJU Int; 2009 May; 103(10):1334-42. PubMed ID: 19338565
[TBL] [Abstract][Full Text] [Related]
32. [Targeted therapies: sequential and combined treatments].
Gross-Goupil M; Escudier B
Bull Cancer; 2010; 97():65-71. PubMed ID: 20418205
[TBL] [Abstract][Full Text] [Related]
33. Management of metastatic renal cell carcinoma progressed after sunitinib or another antiangiogenic treatment.
Iacovelli R; Palazzo A; Trenta P; Mezi S; Pellegrino D; Naso G; Cortesi E
Am J Clin Oncol; 2014 Dec; 37(6):611-5. PubMed ID: 23388560
[TBL] [Abstract][Full Text] [Related]
34. An update on the medical therapy of advanced metastatic renal cell carcinoma.
Kruck S; Merseburger AS; Gakis G; Kramer MW; Stenzl A; Kuczyk MA
Scand J Urol Nephrol; 2008; 42(6):501-6. PubMed ID: 18615363
[TBL] [Abstract][Full Text] [Related]
35. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
[TBL] [Abstract][Full Text] [Related]
36. Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.
Cabebe E; Wakelee H
Curr Treat Options Oncol; 2007 Feb; 8(1):15-27. PubMed ID: 17634832
[TBL] [Abstract][Full Text] [Related]
37. [Antiangiogenics: new therapeutic standards in metastatic kidney cancer].
Cornu JN; Rouprêt M; Bensalah K; Oudard S; Patard JJ
Prog Urol; 2008 Jul; 18 Suppl 4():S69-76. PubMed ID: 18706374
[TBL] [Abstract][Full Text] [Related]
38. Renal cell carcinoma: the translation of molecular biology into new treatments, new patient outcomes, and nursing implications.
Moldawer NP; Figlin R
Oncol Nurs Forum; 2008 Jul; 35(4):699-708. PubMed ID: 18591174
[TBL] [Abstract][Full Text] [Related]
39. [Management of side effects associated with antiangiogenic treatment in renal cell carcinoma].
Fléchon A; Boyle H; Négrier S
Bull Cancer; 2010; 97():73-82. PubMed ID: 20418206
[TBL] [Abstract][Full Text] [Related]
40. Evolving role of novel targeted agents in renal cell carcinoma.
Hutson TE; Figlin RA
Oncology (Williston Park); 2007 Sep; 21(10):1175-80; discussion 1184, 1187, 1190. PubMed ID: 17926797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]